Has your child been affected by neuroblastoma? Call 020 7284 0800 for help and information.

Latest News

Joint statement in response to NICE’s decision to approve anti-GD2 antibody therapy dinutuximab beta for NHS clinical use

Stephen Richards, Chief Executive of Solving Kids’ Cancer, said: “We are absolutely delighted that the right decision has been made to benefit the lives of children with neuroblastoma.  Parents, charities and clinicians have together helped bring about this positive result. Families now know their very sick child will be able to have the best treatment

Read story

Save the date! 2018 Neuroblastoma Parent Education Conference

About the event Our 7th annual Neuroblastoma Parent Education Conference will take place on 2nd – 4th November 2018 at DeVere Latimer Estate conference centre in Buckinghamshire.  If you’re a parent or guardian of a child affected by neuroblastoma, we’d love to meet you!   The event is a unique chance to learn about some of

Read story

Pioneering children’s cancer research role to speed up crucial clinical trials

We’re delighted to let you know about our funding of a ground-breaking role to enable more children with neuroblastoma to access potentially life-saving clinical trials more quickly. In the first dedicated position focusing on a single childhood cancer, Dr Emmanouela Gbandi was appointed as the Solving Kids’ Cancer Senior Trials Coordinator for Neuroblastoma at the

Read story

Anti-GD2 Antibody Therapy Update, May 2018

Following the recent provisional decision by the National Institute for Health and Care Excellence (NICE) not to approve dinutuximab beta (Qarziba™) for use on the NHS in England and Wales, we have updated our briefing document. This was produced by Nick Bird (Parent, Research and Advocacy Trustee and member of the National Cancer Research Institute

Read story

Urgent appeal for Kira Noble smashes target!

Thanks to enormous public generosity and huge fundraising efforts, as of today (8th May) more than £370,000 has been raised for 14-year-old Kira Noble’s life-saving cancer treatment in New York. Kira has been fighting neuroblastoma since she was just 11, and has endured years of gruelling treatment to try to get rid of her disease.

Read story

Joint statement in response to NICE’s preliminary decision on Anti-GD2 antibody therapy dinutuximab beta for NHS clinical use.

From Solving Kids’ Cancer, Neuroblastoma UK, the Children’s Cancer and Leukaemia group, JACK, The Bradley Lowery Foundation, Hugs from Henry, Christopher’s Smile, Niamh’s Next Steps and Smile with Siddy. Charities and Clinicians that support children with high-risk neuroblastoma and their families have joined together in response to the decision not to recommend a life-saving drug

Read story

Urgent appeal launched to help Kira Noble

Help us raise £340,000 by 10th May for 14-year-old Kira Noble’s life-saving cancer treatment in New York. Kira has been fighting neuroblastoma since she was just 11, and has endured years of gruelling treatment to try to get rid of her disease. Sadly, despite best medical efforts it was not possible to remove a growing

Read story

Generosity of an anonymous donor benefits children with cancer

Thanks to an anonymous and generous donor, children’s cancer charities including Solving Kids’ Cancer have benefited from the sale of a valuable sculpture. Called ‘The Boy with the Dolphin’ by David Wynne it was auctioned recently at Christie’s for an amazing £80,000! The money will be split between our charity and other great causes Abbie’s

Read story

Solving Kids’ Cancer wins charity of the month poll

Exciting news! We are delighted to announce that we won the My Favourite Voucher Codes March charity of the month poll. We’d like to say a HUGE thank you to everyone who kindly voted for us.  Your support will help us continue making a difference for children with neuroblastoma and their families, through funding ground-breaking

Read story

Anti-GD2 Antibody Therapy Update, March 2018

A NICE committee hearing will be held on 11th April to discuss whether or not to recommend dinutuximab beta antibody therapy for NHS use. An application has been received from pharmaceutical company EUSA Pharma (who hold the European and UK licence). As we know, dinutuximab beta is an essential treatment that offers hope in the

Read story
Page 1 of 1712345...10...Last »

Join our newsletter

Privacy Policy (click to expand)

Follow us

Useful links

Contact us

Solving Kids' Cancer

Tel: 020 7284 0800

CAN Mezzanine
49-51 East Road
London
N1 6AH

Contact us

Share This